<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04013191</url>
  </required_header>
  <id_info>
    <org_study_id>UP0053</org_study_id>
    <nct_id>NCT04013191</nct_id>
  </id_info>
  <brief_title>A Study to Test the Safety and Tolerability of Single and Multiple Doses of Padsevonil in Adult and Elderly Study Participants</brief_title>
  <official_title>An Open-Label, Parallel-Group, Pharmacokinetic, Safety and Tolerability Study of Single and Multiple Oral Administrations of Padsevonil in Adult and Elderly Study Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Biopharma S.P.R.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the plasma pharmacokinetic of padsevonil in adult and&#xD;
      elderly study participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 9, 2019</start_date>
  <completion_date type="Actual">October 3, 2019</completion_date>
  <primary_completion_date type="Actual">October 3, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Maximum Plasma Concentration (Cmax) of a Single Dose Padsevonil (PSL)</measure>
    <time_frame>Plasma samples were taken predose on Day 1 and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8, 12, 24, 48 and 72 hours postdose</time_frame>
    <description>Cmax was measured in nanograms per milliliter (ng/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Area Under the Curve From 0 to t (AUC0-t) of a Single Dose Padsevonil (PSL)</measure>
    <time_frame>Plasma samples were taken predose on Day 1 and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8, 12, 24, 48 and 72 hours postdose</time_frame>
    <description>AUC0-t: area under the plasma concentration-time curve from time 0 to the last quantifiable concentration. It was measured in hours times nanograms per milliliter (h*ng/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Area Under the Curve (AUC) of a Single Dose Padsevonil (PSL)</measure>
    <time_frame>Plasma samples were taken predose on Day 1 and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8, 12, 24, 48 and 72 hours postdose</time_frame>
    <description>AUC was measured in hours times nanograms per milliliter (h*ng/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Maximum Plasma Concentration at Steady-state (Cmax, ss) of Multiple Doses Padsevonil (PSL)</measure>
    <time_frame>Plasma samples were taken predose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 12 hours on Day 13</time_frame>
    <description>Cmax, ss was measured in nanograms per milliliter (ng/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Area Under the Curve (AUCtau) Over a Dosing Interval of Multiple Doses Padsevonil (PSL)</measure>
    <time_frame>Plasma samples were taken predose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 12 hours on Day 13</time_frame>
    <description>AUCtau was measured in hours times nanograms per milliliter (h*ng/mL).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Amount of Padsevonil (PSL) Excreted in Urine</measure>
    <time_frame>Urine samples were taken on Day 1, Day 2, Day 3, Day 4 and Day 13</time_frame>
    <description>Samples were taken to assess the amount of padsevonil that was excreted in urine. Ae,ss refers to cumulative amount of PSL excreted in the urine at steady state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Ratio of Padsevonil (PSL) to Its Metabolites Excreted in Urine</measure>
    <time_frame>Urine samples were taken on Day 1, Day 2, Day 3, Day 4 and Day 13</time_frame>
    <description>Samples were taken to assess the metabolic ratio of padsevonil that was excreted in urine. MRAe was defined as the metabolic ratio of PSL to its metabolites for cumulative amount of PSL metabolites excreted in the urine. ss refers to steady state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events</measure>
    <time_frame>From Baseline until End-of-Treatment visit (up to Day 22)</time_frame>
    <description>An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. An AE could, therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events</measure>
    <time_frame>From Baseline until End-of-Treatment visit (up to Day 22)</time_frame>
    <description>A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose:&#xD;
Results in death&#xD;
Is life-threatening&#xD;
Requires in patient hospitalization or prolongation of existing hospitalization&#xD;
Is a congenital anomaly or birth defect&#xD;
Is an infection that requires treatment parenteral antibiotics&#xD;
Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events Leading to Discontinuation of the Study</measure>
    <time_frame>From Baseline until End-of-Treatment visit (up to Day 22)</time_frame>
    <description>An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Elderly Study Participants</condition>
  <condition>Adult Study Participants</condition>
  <arm_group>
    <arm_group_label>Adult study participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive assigned single and multiple doses of padsevonil.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elderly study participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive assigned single and multiple doses of padsevonil.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Padsevonil</intervention_name>
    <description>Padsevonil will be administered in predefined dosages.</description>
    <arm_group_label>Adult study participants</arm_group_label>
    <arm_group_label>Elderly study participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Study participants in the adult cohort must be ≥18 to 64 years of age at the time of&#xD;
             signing the informed consent form (ICF)&#xD;
&#xD;
          -  Study participants in the elderly cohort must be ≥65 years of age at the time of&#xD;
             signing the ICF&#xD;
&#xD;
          -  Study participants who are overtly healthy as determined by medical evaluation,&#xD;
             including medical history, physical examination, laboratory tests, and cardiac&#xD;
             monitoring. In addition, elderly study participants must be considered to be in&#xD;
             general good physical and mental health&#xD;
&#xD;
          -  Study participants must have a body weight of at least 50 kg for males and 45 kg for&#xD;
             females, and a body mass index within the range of 18 to 32 kg/m2 (inclusive)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Study participant has a current or past psychiatric condition that, in the opinion of&#xD;
             the Investigator, could compromise the study participant's safety or ability to&#xD;
             participate in this study, or a history of schizophrenia or other psychotic disorder,&#xD;
             bipolar disorder, or severe unipolar depression. The presence of potential psychiatric&#xD;
             exclusion criteria will be determined based on the psychiatric history collected at&#xD;
             Screening&#xD;
&#xD;
          -  Study participant has history or presence of cardiovascular, respiratory, hepatic,&#xD;
             renal, gastrointestinal, endocrinological, hematological, or neurological disorders&#xD;
             capable of significantly altering the absorption, metabolism, or elimination of drugs;&#xD;
             constituting a risk when taking the study intervention; or interfering with the&#xD;
             interpretation of data&#xD;
&#xD;
          -  Study participant has a known hypersensitivity to any components of the study&#xD;
             medication as stated in this protocol&#xD;
&#xD;
          -  Subject has a history of unexplained syncope or a family history of sudden death due&#xD;
             to long QT syndrome&#xD;
&#xD;
          -  Study participant has abnormal blood pressure&#xD;
&#xD;
          -  Study participant has had lymphoma, leukemia, or any malignancy within the past 5&#xD;
             years, except for basal cell or squamous epithelial carcinomas of the skin that have&#xD;
             been resected with no evidence of metastatic disease for 3 years&#xD;
&#xD;
          -  Study participant has a lifetime history of suicide attempt, or has had suicidal&#xD;
             ideation in the past 6 months as indicated by a positive response (&quot;Yes&quot;) to either&#xD;
             Question 4 or Question 5 of the &quot;Screening/Baseline&quot; version of the Columbia-Suicide&#xD;
             Severity Rating Scale (C-SSRS) at Screening&#xD;
&#xD;
          -  Study participant has past or intended use of over-the-counter or prescription&#xD;
             medication, including herbal medications within 2 weeks or 5 half-lives prior to&#xD;
             dosing&#xD;
&#xD;
          -  The study participant has used hepatic enzyme-inducing drugs within 2 months prior to&#xD;
             dosing&#xD;
&#xD;
          -  Study participant has previously received padsevonil (PSL) in this or another study&#xD;
&#xD;
          -  Study participant has alanine aminotransferase (ALT), aspartate aminotransferase&#xD;
             (AST), or alkaline phosphatase (ALP) &gt;1.0x upper limit of normal (ULN)&#xD;
&#xD;
          -  Study participant has bilirubin &gt;1.0xULN (isolated bilirubin &gt;1.0xULN is acceptable if&#xD;
             bilirubin is fractionated and direct bilirubin &lt;35%)&#xD;
&#xD;
          -  Study participant has current or chronic history of liver disease or known hepatic or&#xD;
             biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic&#xD;
             gallstones)&#xD;
&#xD;
          -  Study participant has any clinically relevant electrocardiogram (ECG) finding at&#xD;
             Screening or at Baseline. Study participant has an abnormality in the 12-lead ECG&#xD;
             that, in the opinion of the Investigator, increases the risks associated with&#xD;
             participating in the study. In addition, any study participant with any of the&#xD;
             following findings will be excluded: (a) QT interval corrected for heart rate using&#xD;
             Bazett's formula (QTcB) or Fridericia's formula (QTcF) &gt;450 ms in study participants&#xD;
             in 2 of 3 ECG recordings; (b) other conduction abnormalities (defined as PR interval&#xD;
             ≥220 ms); (c) irregular rhythms other than sinus arrhythmia or occasional, rare&#xD;
             supraventricular or rare ventricular ectopic beats. In case of an out of range result,&#xD;
             1 repeat will be allowed. If out of range again, the study participant cannot be&#xD;
             included&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Cares</last_name>
    <role>Study Director</role>
    <affiliation>001 844 599 2273 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Up0053 001</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 5, 2019</study_first_submitted>
  <study_first_submitted_qc>July 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2019</study_first_posted>
  <results_first_submitted>April 30, 2021</results_first_submitted>
  <results_first_submitted_qc>June 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 30, 2021</results_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Padsevonil</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Pharmacokinetic</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Due to the small sample size in this trial, Individual Patient Data cannot be adequately anonymized and there is a reasonable likelihood that individual participants could be re-identified. For this reason, data from this trial cannot be shared.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 29, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/91/NCT04013191/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 18, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/91/NCT04013191/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study started to enroll patients in July 2019 and concluded in October 2019.</recruitment_details>
      <pre_assignment_details>The study included a 28 days Screening period, a 21 days Treatment period: Period 1A single dose (SD) on Days 1 to 7 and Period 1B multiple dose (MD) on Days 8 to 21 and a Safety Follow-up period on Day 22.&#xD;
Participant Flow refers to the Full Analysis Set.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Adults (18-64 Years)</title>
          <description>Participants received assigned single and multiple doses of padsevonil.</description>
        </group>
        <group group_id="P2">
          <title>Elderly (&gt;= 65 Years)</title>
          <description>Participants received assigned single and multiple doses of padsevonil.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Period 1A (Single Dose)</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Period 1B (Multiple Dose)</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline Characteristics refer to Full Analysis Set (FAS) which consisted of all study participants who signed the informed consent form (ICF) and received at least 1 dose of PSL.</population>
      <group_list>
        <group group_id="B1">
          <title>Adults (18-64 Years)</title>
          <description>Participants received assigned single and multiple doses of padsevonil.</description>
        </group>
        <group group_id="B2">
          <title>Elderly (&gt;= 65 Years)</title>
          <description>Participants received assigned single and multiple doses of padsevonil.</description>
        </group>
        <group group_id="B3">
          <title>Total Title</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.4" spread="10.2"/>
                    <measurement group_id="B2" value="69.7" spread="4.5"/>
                    <measurement group_id="B3" value="60.6" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Maximum Plasma Concentration (Cmax) of a Single Dose Padsevonil (PSL)</title>
        <description>Cmax was measured in nanograms per milliliter (ng/mL).</description>
        <time_frame>Plasma samples were taken predose on Day 1 and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8, 12, 24, 48 and 72 hours postdose</time_frame>
        <population>The Pharmacokinetic-Per Protocol Set (PK-PPS) was a subset of the FAS, consisting of study participants who had no important protocol deviation (IPD) affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Adults (18-64 Years) (PK-PPS)</title>
            <description>Participants received assigned single and multiple doses of padsevonil, forming the Pharmacokinetic-Per Protocol Set (PK-PPS).</description>
          </group>
          <group group_id="O2">
            <title>Elderly (&gt;= 65 Years) (PK-PPS)</title>
            <description>Participants received assigned single and multiple doses of padsevonil, forming the PK-PPS.</description>
          </group>
        </group_list>
        <measure>
          <title>The Maximum Plasma Concentration (Cmax) of a Single Dose Padsevonil (PSL)</title>
          <description>Cmax was measured in nanograms per milliliter (ng/mL).</description>
          <population>The Pharmacokinetic-Per Protocol Set (PK-PPS) was a subset of the FAS, consisting of study participants who had no important protocol deviation (IPD) affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter.</population>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="903.6" lower_limit="712" upper_limit="1150"/>
                    <measurement group_id="O2" value="838.4" lower_limit="702" upper_limit="1000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis of variance (ANOVA) model included the fixed effects of age group. The natural logs were taken of the dependent variables and back-transformed after the analysis.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Point Estimate</param_type>
            <param_value>0.928</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.725</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Area Under the Curve From 0 to t (AUC0-t) of a Single Dose Padsevonil (PSL)</title>
        <description>AUC0-t: area under the plasma concentration-time curve from time 0 to the last quantifiable concentration. It was measured in hours times nanograms per milliliter (h*ng/mL).</description>
        <time_frame>Plasma samples were taken predose on Day 1 and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8, 12, 24, 48 and 72 hours postdose</time_frame>
        <population>The Pharmacokinetic-Per Protocol Set (PK-PPS) was a subset of the FAS, consisting of study participants who had no important protocol deviation (IPD) affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Adults (18-64 Years) (PK-PPS)</title>
            <description>Participants received assigned single and multiple doses of padsevonil, forming the Pharmacokinetic-Per Protocol Set (PK-PPS).</description>
          </group>
          <group group_id="O2">
            <title>Elderly (&gt;= 65 Years) (PK-PPS)</title>
            <description>Participants received assigned single and multiple doses of padsevonil, forming the PK-PPS.</description>
          </group>
        </group_list>
        <measure>
          <title>The Area Under the Curve From 0 to t (AUC0-t) of a Single Dose Padsevonil (PSL)</title>
          <description>AUC0-t: area under the plasma concentration-time curve from time 0 to the last quantifiable concentration. It was measured in hours times nanograms per milliliter (h*ng/mL).</description>
          <population>The Pharmacokinetic-Per Protocol Set (PK-PPS) was a subset of the FAS, consisting of study participants who had no important protocol deviation (IPD) affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter.</population>
          <units>h*ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4915" lower_limit="3630" upper_limit="6650"/>
                    <measurement group_id="O2" value="6011" lower_limit="4800" upper_limit="7530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The ANOVA model included the fixed effects of age group. The natural logs were taken of the dependent variables and back-transformed after the analysis.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Point Estimate</param_type>
            <param_value>1.22</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.894</ci_lower_limit>
            <ci_upper_limit>1.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Area Under the Curve (AUC) of a Single Dose Padsevonil (PSL)</title>
        <description>AUC was measured in hours times nanograms per milliliter (h*ng/mL).</description>
        <time_frame>Plasma samples were taken predose on Day 1 and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8, 12, 24, 48 and 72 hours postdose</time_frame>
        <population>The Pharmacokinetic-Per Protocol Set (PK-PPS) was a subset of the FAS, consisting of study participants who had no important protocol deviation (IPD) affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Adults (18-64 Years) (PK-PPS)</title>
            <description>Participants received assigned single and multiple doses of padsevonil, forming the Pharmacokinetic-Per Protocol Set (PK-PPS).</description>
          </group>
          <group group_id="O2">
            <title>Elderly (&gt;= 65 Years) (PK-PPS)</title>
            <description>Participants received assigned single and multiple doses of padsevonil, forming the PK-PPS.</description>
          </group>
        </group_list>
        <measure>
          <title>The Area Under the Curve (AUC) of a Single Dose Padsevonil (PSL)</title>
          <description>AUC was measured in hours times nanograms per milliliter (h*ng/mL).</description>
          <population>The Pharmacokinetic-Per Protocol Set (PK-PPS) was a subset of the FAS, consisting of study participants who had no important protocol deviation (IPD) affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter.</population>
          <units>h*ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4950" lower_limit="3650" upper_limit="6720"/>
                    <measurement group_id="O2" value="6061" lower_limit="4830" upper_limit="7610"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The ANOVA model included the fixed effects of age group. The natural logs were taken of the dependent variables and back-transformed after the analysis.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Point Estimate</param_type>
            <param_value>1.22</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.893</ci_lower_limit>
            <ci_upper_limit>1.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Maximum Plasma Concentration at Steady-state (Cmax, ss) of Multiple Doses Padsevonil (PSL)</title>
        <description>Cmax, ss was measured in nanograms per milliliter (ng/mL).</description>
        <time_frame>Plasma samples were taken predose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 12 hours on Day 13</time_frame>
        <population>The PK-PPS was a subset of the FAS, consisting of study participants who had no IPD affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter. 1 participant in the adult cohort discontinued due to a treatment emergent adverse event (TEAE) after 5 days of PSL administration in the MD Period.</population>
        <group_list>
          <group group_id="O1">
            <title>Adults (18-64 Years) (PK-PPS)</title>
            <description>Participants received assigned single and multiple doses of padsevonil, forming the Pharmacokinetic-Per Protocol Set (PK-PPS).</description>
          </group>
          <group group_id="O2">
            <title>Elderly (&gt;= 65 Years) (PK-PPS)</title>
            <description>Participants received assigned single and multiple doses of padsevonil, forming the PK-PPS.</description>
          </group>
        </group_list>
        <measure>
          <title>The Maximum Plasma Concentration at Steady-state (Cmax, ss) of Multiple Doses Padsevonil (PSL)</title>
          <description>Cmax, ss was measured in nanograms per milliliter (ng/mL).</description>
          <population>The PK-PPS was a subset of the FAS, consisting of study participants who had no IPD affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter. 1 participant in the adult cohort discontinued due to a treatment emergent adverse event (TEAE) after 5 days of PSL administration in the MD Period.</population>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1157" lower_limit="942" upper_limit="1420"/>
                    <measurement group_id="O2" value="1180" lower_limit="1020" upper_limit="1360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The ANOVA model included the fixed effects of age group. The natural logs were taken of the dependent variables and back-transformed after the analysis.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Point Estimate</param_type>
            <param_value>1.02</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.829</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Area Under the Curve (AUCtau) Over a Dosing Interval of Multiple Doses Padsevonil (PSL)</title>
        <description>AUCtau was measured in hours times nanograms per milliliter (h*ng/mL).</description>
        <time_frame>Plasma samples were taken predose and 0.25, 0.5, 0.75, 1, 1.5, 3, 4, 6, 8 and 12 hours on Day 13</time_frame>
        <population>The PK-PPS was a subset of the FAS, consisting of study participants who had no IPD affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter. 1 participant in the adult cohort discontinued due to a TEAE after 5 days of PSL administration in the MD Period.</population>
        <group_list>
          <group group_id="O1">
            <title>Adults (18-64 Years) (PK-PPS)</title>
            <description>Participants received assigned single and multiple doses of padsevonil, forming the Pharmacokinetic-Per Protocol Set (PK-PPS).</description>
          </group>
          <group group_id="O2">
            <title>Elderly (&gt;= 65 Years) (PK-PPS)</title>
            <description>Participants received assigned single and multiple doses of padsevonil, forming the PK-PPS.</description>
          </group>
        </group_list>
        <measure>
          <title>The Area Under the Curve (AUCtau) Over a Dosing Interval of Multiple Doses Padsevonil (PSL)</title>
          <description>AUCtau was measured in hours times nanograms per milliliter (h*ng/mL).</description>
          <population>The PK-PPS was a subset of the FAS, consisting of study participants who had no IPD affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter. 1 participant in the adult cohort discontinued due to a TEAE after 5 days of PSL administration in the MD Period.</population>
          <units>h*ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5346" lower_limit="4130" upper_limit="6920"/>
                    <measurement group_id="O2" value="6307" lower_limit="5260" upper_limit="7570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The ANOVA model included the fixed effects of age group. The natural logs were taken of the dependent variables and back-transformed after the analysis.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Point Estimate</param_type>
            <param_value>1.18</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.908</ci_lower_limit>
            <ci_upper_limit>1.53</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Amount of Padsevonil (PSL) Excreted in Urine</title>
        <description>Samples were taken to assess the amount of padsevonil that was excreted in urine. Ae,ss refers to cumulative amount of PSL excreted in the urine at steady state.</description>
        <time_frame>Urine samples were taken on Day 1, Day 2, Day 3, Day 4 and Day 13</time_frame>
        <population>The Pharmacokinetic-Per Protocol Set (PK-PPS) was a subset of the FAS, consisting of study participants who had no important protocol deviation (IPD) affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Adults (18-64 Years) (PK-PPS)</title>
            <description>Participants received assigned single and multiple doses of padsevonil, forming the Pharmacokinetic-Per Protocol Set (PK-PPS).</description>
          </group>
          <group group_id="O2">
            <title>Elderly (&gt;= 65 Years) (PK-PPS)</title>
            <description>Participants received assigned single and multiple doses of padsevonil, forming the PK-PPS.</description>
          </group>
        </group_list>
        <measure>
          <title>The Amount of Padsevonil (PSL) Excreted in Urine</title>
          <description>Samples were taken to assess the amount of padsevonil that was excreted in urine. Ae,ss refers to cumulative amount of PSL excreted in the urine at steady state.</description>
          <population>The Pharmacokinetic-Per Protocol Set (PK-PPS) was a subset of the FAS, consisting of study participants who had no important protocol deviation (IPD) affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter.</population>
          <units>milligrams</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Single dose: Day 1 (Ae)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0862" spread="153.9"/>
                    <measurement group_id="O2" value="0.0979" spread="45.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple dose: Day 13 (Ae,ss)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0924" spread="109.5"/>
                    <measurement group_id="O2" value="0.166" spread="45.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite 1, Single dose: Day 1 (Ae)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.941" spread="79.9"/>
                    <measurement group_id="O2" value="1.13" spread="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite 1, Multiple dose: Day 13 (Ae,ss)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" spread="96.9"/>
                    <measurement group_id="O2" value="1.86" spread="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite 2, Single dose: Day 1 (Ae)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" spread="68.3"/>
                    <measurement group_id="O2" value="14.6" spread="54.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite 2, Multiple dose: Day 13 (Ae,ss)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" spread="79.5"/>
                    <measurement group_id="O2" value="14.4" spread="45.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Ratio of Padsevonil (PSL) to Its Metabolites Excreted in Urine</title>
        <description>Samples were taken to assess the metabolic ratio of padsevonil that was excreted in urine. MRAe was defined as the metabolic ratio of PSL to its metabolites for cumulative amount of PSL metabolites excreted in the urine. ss refers to steady state.</description>
        <time_frame>Urine samples were taken on Day 1, Day 2, Day 3, Day 4 and Day 13</time_frame>
        <population>The Pharmacokinetic-Per Protocol Set (PK-PPS) was a subset of the FAS, consisting of study participants who had no important protocol deviation (IPD) affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>Adults (18-64 Years) (PK-PPS)</title>
            <description>Participants received assigned single and multiple doses of padsevonil, forming the Pharmacokinetic-Per Protocol Set (PK-PPS).</description>
          </group>
          <group group_id="O2">
            <title>Elderly (&gt;= 65 Years) (PK-PPS)</title>
            <description>Participants received assigned single and multiple doses of padsevonil, forming the PK-PPS.</description>
          </group>
        </group_list>
        <measure>
          <title>The Ratio of Padsevonil (PSL) to Its Metabolites Excreted in Urine</title>
          <description>Samples were taken to assess the metabolic ratio of padsevonil that was excreted in urine. MRAe was defined as the metabolic ratio of PSL to its metabolites for cumulative amount of PSL metabolites excreted in the urine. ss refers to steady state.</description>
          <population>The Pharmacokinetic-Per Protocol Set (PK-PPS) was a subset of the FAS, consisting of study participants who had no important protocol deviation (IPD) affecting the PK parameters and for whom a sufficient number of samples were available to determine at least 1 PK parameter.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Metabolite 1, Single dose: Day 1 (MRAe)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" spread="52.8"/>
                    <measurement group_id="O2" value="11.2" spread="40.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite 1, Multiple dose: Day 13 (MRAe,ss)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" spread="43.9"/>
                    <measurement group_id="O2" value="10.9" spread="38.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite 2, Single dose: Day 1 (MRAe)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217" spread="122.3"/>
                    <measurement group_id="O2" value="149" spread="81.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolite 2, Multiple dose: Day 13 (MRAe,ss)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144" spread="81.1"/>
                    <measurement group_id="O2" value="86.8" spread="67.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-emergent Adverse Events</title>
        <description>An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. An AE could, therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study medication.</description>
        <time_frame>From Baseline until End-of-Treatment visit (up to Day 22)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all study participants who signed the informed consent form (ICF) and received at least 1 dose of PSL.</population>
        <group_list>
          <group group_id="O1">
            <title>Adults (18-64 Years) (FAS)</title>
            <description>Participants received assigned single and multiple doses of padsevonil, forming the Full Analysis Set (FAS).</description>
          </group>
          <group group_id="O2">
            <title>Elderly (&gt;= 65 Years) (FAS)</title>
            <description>Participants received assigned single and multiple doses of padsevonil, forming the FAS.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Adverse Events</title>
          <description>An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. An AE could, therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study medication.</description>
          <population>The Full Analysis Set (FAS) consisted of all study participants who signed the informed consent form (ICF) and received at least 1 dose of PSL.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Single Dose Period (1A)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple Dose Period (1B)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events</title>
        <description>A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose:&#xD;
Results in death&#xD;
Is life-threatening&#xD;
Requires in patient hospitalization or prolongation of existing hospitalization&#xD;
Is a congenital anomaly or birth defect&#xD;
Is an infection that requires treatment parenteral antibiotics&#xD;
Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above</description>
        <time_frame>From Baseline until End-of-Treatment visit (up to Day 22)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all study participants who signed the informed consent form (ICF) and received at least 1 dose of PSL.</population>
        <group_list>
          <group group_id="O1">
            <title>Adults (18-64 Years) (FAS)</title>
            <description>Participants received assigned single and multiple doses of padsevonil, forming the Full Analysis Set (FAS).</description>
          </group>
          <group group_id="O2">
            <title>Elderly (&gt;= 65 Years) (FAS)</title>
            <description>Participants received assigned single and multiple doses of padsevonil, forming the FAS.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events</title>
          <description>A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose:&#xD;
Results in death&#xD;
Is life-threatening&#xD;
Requires in patient hospitalization or prolongation of existing hospitalization&#xD;
Is a congenital anomaly or birth defect&#xD;
Is an infection that requires treatment parenteral antibiotics&#xD;
Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above</description>
          <population>The Full Analysis Set (FAS) consisted of all study participants who signed the informed consent form (ICF) and received at least 1 dose of PSL.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Single Dose Period (1A)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple Dose Period (1B)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-emergent Adverse Events Leading to Discontinuation of the Study</title>
        <description>An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.</description>
        <time_frame>From Baseline until End-of-Treatment visit (up to Day 22)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all study participants who signed the informed consent form (ICF) and received at least 1 dose of PSL.</population>
        <group_list>
          <group group_id="O1">
            <title>Adults (18-64 Years) (FAS)</title>
            <description>Participants received assigned single and multiple doses of padsevonil, forming the Full Analysis Set (FAS).</description>
          </group>
          <group group_id="O2">
            <title>Elderly (&gt;= 65 Years) (FAS)</title>
            <description>Participants received assigned single and multiple doses of padsevonil, forming the FAS.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Adverse Events Leading to Discontinuation of the Study</title>
          <description>An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.</description>
          <population>The Full Analysis Set (FAS) consisted of all study participants who signed the informed consent form (ICF) and received at least 1 dose of PSL.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Single Dose Period (1A)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple Dose Period (1B)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment emergent adverse events were collected from Baseline until End-of-Treatment visit (up to Day 22)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Adults (18-64 Years) (FAS) SD Period (1A)</title>
          <description>Participants received a single dose of padsevonil during Period (1A), forming the FAS.</description>
        </group>
        <group group_id="E2">
          <title>Elderly (&gt;= 65 Years) (FAS) SD Period (1A)</title>
          <description>Participants received a single dose of padsevonil during Period (1A), forming the FAS.</description>
        </group>
        <group group_id="E3">
          <title>Adults (18-64 Years) (FAS) MD Period (1B)</title>
          <description>Participants received multiple doses of padsevonil during Period (1B), forming the FAS.</description>
        </group>
        <group group_id="E4">
          <title>Elderly (&gt;= 65 Years) (FAS) MD Period (1B)</title>
          <description>Participants received multiple doses of padsevonil during Period (1B), forming the FAS.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA22.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutrophilia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure systolic decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="18"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E4" events="16" subjects_affected="16" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Disinhibition</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Enuresis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Initial insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin erosion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>UCB</name_or_title>
      <organization>Cares</organization>
      <phone>+1844 599 ext 2273</phone>
      <email>clinicaltrials@ucb.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

